Article
[Effectiveness of erlotinib in Critical Care Unit in patients with non-small cell lung cancer with EGFR mutation].
Revue de pneumologie clinique - 1 Jun 2017
Dewolf M, Dayen C, Garoute C, Khamis W, Fourrier M, Rousselle F, Sadki M, Le Meunier F, Suguenot R, Lecuyer E, Bentayeb H, Douadi Y, Berna P
Abstract excerpt
INTRODUCTION: The search for mutations epidermal growth factor receptor (EGFR) has changed the therapeutic approach and prognosis of non-small cell lung cancer (NSCLC). The effectiveness of tyrosine kinase inhibitors (TKI) has been demonstrated orally in patients with EGFR mutation. We report the case of a patient for whom treatment with TKI was started effectively in a Critical Care Unit. OBSERVATION: A patient...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.